+147.7%
AMKR vs GSK
+47.2%
+100.6%
-65.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.4% | 0.0% | +4.4% | +4.4% |
| 7D | +8.3% | -3.5% | +11.8% | +8.3% |
| 30D | -6.8% | -3.4% | -3.3% | -6.9% |
| 3M | -31.9% | -8.1% | -23.8% | -31.9% |
| 6M | +18.4% | -11.1% | +29.5% | +19.2% |
| YTD | +31.7% | +0.7% | +30.9% | +30.2% |
| 1Y | +105.2% | +20.1% | +85.1% | +97.7% |
| 3Y | +147.7% | +46.1% | +101.6% | +140.3% |
| All | +147.7% | +47.2% | +100.6% | +140.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling